Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12753941 | 1.00 | CPA1 (0.39) | CPA1PTGS1PTGS2GSRTSHR | |
| SCHEMBL12753943 | 1.00 | CPA1 (0.39) | CPA1PTGS1PTGS2GSRTSHR | |
| SCHEMBL11669919 | 0.92 | PTGS1 (0.33) | CPA1PTGS1PTGS2GSRTSHR | |
| SCHEMBL14849944 | 0.85 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL14607628 | 0.83 | PTGS1 (0.30) | PTGS1PTGS2 | |
| SCHEMBL14476657 | 0.81 | PTGS1 (0.33) | PTGS1PTGS2GSRTSHR | |
| SCHEMBL12753910 | 0.80 | CA1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL12753883 | 0.80 | CA1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL12753913 | 0.80 | CA1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL324234 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | CPA1 919/4885PTGS1 656/4885PTGS2 428/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | CPA1 911/4885PTGS1 56/4885PTGS2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.